Psychiatry

Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

William Sauve, MD shares the growing landscape of treatments for treatment resistant depression (TRD) and their mechanism of action, such as brain stimulation through electroconvulsive therapy or medication such as esketamine.

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.

In an interview with HCPLive, Angela Moreland, PhD, highlighted the largest takeaway from the study on the psychiatric impact of mass shootings on the greater community.

In this video series segment, Casey Paleos, MD, provides insight into what he considers to be the most pertinent unanswered questions surrounding MDMA-assisted therapy in PTSD.

In this video series segment, Casey Paleos, MD, discusses his outlook on the potential of psychedelic therapies in PTSD looking forward.

In this video series segment, Casey Paleos, MD, offers insight into the impact of historic stigma associated with psychedelic therapies on acceptance in psychiatric care.

In this video series segment, Casey Paleos, MD, describes his interpretation of clinical trial data for MDMA-assisted therapy in PTSD as well as his reaction to the FDA PDAC vote in early June.

In this video series segment, Casey Paleos, MD, provides perspective on the current options and unmet needs in the management of posttraumatic stress disorder.

In a "secret shopper" study, investigators posing as Medicaid enrollees found many clinicians in Medicaid provider directories do not accept Medicaid insurance.

A year after zuranolone’s FDA approval for postpartum depression on August 3, 2023, prescribers and a patient weigh in about the medication’s success in alleviating symptoms.

This month in review captures the top news in the psychiatry field during July.

This extended-release injectable suspension for schizophrenia and schizoaffective disorder is approved as a monotherapy and as an adjunct to mood stabilizers or antidepressants.

A new study found using e-cigarettes with partial nicotine reduction was linked to greater puffing time, puff duration, and total inhaled volume than 5% nicotine concentration.

A new study found the group with the shortest seizure duration of ≤ 20 seconds had the lowest remission rate of 27.2%, compared with a 39.3% overall remission rate.

Depression A new study discovers a dual pathway framework where antidepressants are concomitantly negatively and positively linked to alcohol use.

A study found wearable devices alerting irregular heart rhythms amplified anxiety in 1 in 5 participants with atrial fibrillation, which led people to be more likely to seek care.

A new study found claims for services of opioid treatment programs rose among Medicare beneficiaries after Medicare started covering them.

A new study found probable PTSD was prevalent among adults in the community after a mass shooting, with greater prevalence among those previously assaulted.

In this part of our 5-part series, Gus Alva, MD discusses the next steps in research for long-term effects and broader applications of MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD explores MDMA’s neurochemical impact and the need for ongoing research.